Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study.
Irene Gonzalez DiazMariana Gutierrez RiartMaria Dolores Martin-ArranzChamaida Plasencia RodriguezCristina Suarez Ferrernull On Behalf Of Vedustar Research TeamPublished in: Journal of clinical medicine (2024)
Our experience shows that treatment with UST and VDZ did not worsen joint disease in patients with SpA. Most remained stable or improved. In addition, poor control of IBD in patients with joint flare-ups could be the main cause of worsening SpA.